Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia

Current Medical Research and Opinion

Volumn 20, Issue 7, 2004, Pages 1039-1048

  Zhao, Zhongyun ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Costs; Olanzapine; Outcomes; Risperidone; Schizophrenia, uncontrolled

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; HYPNOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE SEVERITY; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG UTILIZATION; ECONOMIC EVALUATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEALTH CARE COST; HOSPITAL COST; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; MULTIPLE REGRESSION; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; OUTPATIENT CARE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COHORT STUDIES; DATABASES; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS;

EID: 3242679080     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125004097     Document Type: Article

References (40)

1. Andreasen NC. Assessment issues and the cost of schizophrenia. Schizophr Bull 1991;17:475-81
2. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry Suppl 1994:18-21
3. Knapp M. Costs of schizophrenia. Br J Psychiatry 1997;171:509-18
4. Rice DP, Miller LS. The Economic Burden of Schizophrenia. Conceptual and Methodological Issues, and Cost Estimates. In: Moscarelli M, Rupp A, Sartorius N, eds. Handbook of Mental Health Economics and Health Policy. Vol, I: Schizophrenia. John Wiley and Sons, 1996
5. Wyatt RJ, Henter I, Leary MC, Taylor E. An economic evaluation of schizophrenia - 1991. Soc Psychiatry Psychiatr Epidemiol 1995;30:196-205
6. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia [see comments]. N Engl J Med 1997;337:809-815
7. Tollefson GD, Beasley CM, Jr., Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65
8. Hamilton S, Revicki D, Edgell E, Genduso L, Tollefson G. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: Results from a randomised clinical trial. Pharmacoeconomics 1999;15:469-480
9. Volavka J, Czobor P, Sheitman B, et al. Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder. Am J Psychiatry 2002;159:255-262; also contains Editorial pages 177-179
10. Association AD, Association AP, Endocrinologists AAoC, Obesity NAAftSo. Consensus Development Conference on Antipsychotic Drug and Obesity and Diabetes. J Clin Psychiatry 2004;65:267-272
11. Henderson DC. Atypical antipsychotic-induced diabetes mellitus - How strong is the evidence? [Review]. CNS Drugs 2002; 16:77-89
12. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-6
13. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96
14. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
15. Sauriol L, Laporta M, Edwardes MD, Deslandes M, Ricard N, Suissa S. Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: Evaluating the indirect approach. Clin Ther 2001;23:942-956
16. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-774
17. Purdon S. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 2000;57
18. Procyshyn RM, Zerjav S. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clin Ther 1998;20:1203-17; discussion 1192-3
19. Rabinowitz J, Lichtenberg P, Kaplan Z. Comparison of cost, dosage and clinical preference for risperidone and olanzapine. Schizophr Res 2000;46:91-96
20. Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A. Olanzapine versus risperidone - A prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 2000;18:567-579
21. Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK: A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 2000;17:383-389
22. Del Paggio D. Economic issues associated with antipsychotic agents. Dir Psychiatr 2000;20:43-48
23. Rascati KL, Johnsrud MT, Crismon ML, Lage MJ, Barber BL. Olanzapine versus risperidone in the treatment of schizophrenia - A comparison of costs among Texas medicaid recipients. Pharmacoeconomics 2003;21:683-697
24. Opolka JL, Rascati KL, Brown CM, Gibson PJ. Role of ethnicity in predicting antipsychotic medication adherence. Ann Pharmacother 2003;37:625-630
25. Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL. The Impact of Olanzapine, Risperidone, or Haloperidol on the Cost of Schizophrenia Care in a Medicaid Population. Value Health 2004;7:22-35
26. Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing health care utilization and costs. Annu Rev Public Health 1999;20:125-44
27. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994;331:650-5
28. Lurie N, Popkin M, Dysken M, Moscovice I, Finch M. Accuracy of diagnoses of schizophrenia in Medicaid claims. Hosp Com Psychiatry 1992;43:69-71
29. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ 1999;18:153-171
30. Bouckaert A, Crott R. The Difference in Mean Costs as a Pharmacoeconomic Outcome Variable: Power Considerations. Control Clin Trials 1997;18:58-64
31. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid Beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-699
32. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461-494
33. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998; 17:283-295
34. Zhao Z, Tunis SL, Lage MJ. Medication treatment patterns following initiation on olanzapine versus risperidone. Clin Drug Invest 2002;22:741-749
35. Fleischhacker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand 1994;89(Suppl 382):11-15
36. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10:133-8
37. Weiden PJ, Shaw E, Man JJ. Causes of neuroleptic non-compliance. Psych Annals 1986:571-5
38. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-429
39. Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia - Economic and clinical issues. Pharmacoeconomics 2000;18:105-124
40. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805-811